BRAVE study will explore the potential of omaveloxolone to address the critical unmet need of the pediatric FA population
The company received seven observations in the Form-483
QuantumNexis will serve as the innovative engine for HCTI's recurring revenue business lines
The company received one observation in the Form-483
The inspection concluded successfully, with the facility found to be in compliance with the required regulations
Sun Pharma gets 8 observations from USFDA for Halol facility
Innovative agents highlight growth of targeted protein degradation platform and BMS' leadership in innovative cancer therapies
Conceptulised by Lowe Lintas, the new campaign creatively brings the "fast action" benefit of Cipladine to life through a series of films
The company received 1 (One) observation in the Form-483
Now approved for both acute and chronic HCV in adults and children aged 3 and above
Subscribe To Our Newsletter & Stay Updated
